Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial PharmaphorumRoche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.OncologyRead full story pharminent July 2, 2026 (Last updated: July 2, 2026) Pharmaphorum Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026 Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026 Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit pharminent June 29, 2026
